THC Therapeutics (THC Therapeutics) Debt-to-Equity : -0.22 (As of Jul. 2023)

View and export this data going back to 2007. Start your Free Trial

What is THC Therapeutics Debt-to-Equity?

THC Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.73 Mil. THC Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.00 Mil. THC Therapeutics's Total Stockholders Equity for the quarter that ended in Jul. 2023 was $-3.31 Mil. THC Therapeutics's debt to equity for the quarter that ended in Jul. 2023 was -0.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for THC Therapeutics's Debt-to-Equity or its related term are showing as below:

THCT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.83 Med: -0.28 Max: 0.09
Current: -0.22

During the past 13 years, the highest Debt-to-Equity Ratio of THC Therapeutics was 0.09. The lowest was -0.83. And the median was -0.28.

THCT's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs THCT: -0.22

THC Therapeutics Debt-to-Equity Historical Data

The historical data trend for THC Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

THC Therapeutics Debt-to-Equity Chart

THC Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Debt-to-Equity

Get a 7-Day Free Trial

-0.24

-0.25

-0.31

-0.26

-0.22

THC Therapeutics Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Debt-to-Equity	Get a 7-Day Free Trial															-0.26	-0.14	-0.22	-0.22	-0.22

Competitive Comparison of THC Therapeutics's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, THC Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

THC Therapeutics's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, THC Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where THC Therapeutics's Debt-to-Equity falls into.

THC Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

THC Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.732	+	0)	/	-3.31
	=	-0.22

THC Therapeutics's Debt to Equity Ratio for the quarter that ended in Jul. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.732	+	0)	/	-3.31
	=	-0.22

THC Therapeutics (OTCPK:THCT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

THC Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of THC Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

THC Therapeutics (THC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » THC Therapeutics Inc (OTCPK:THCT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

11700 W Charleston Boulevard, No. 73, Las Vegas, NV, USA, 89135

Website

https://thct.io

THC Therapeutics Inc is a United States-based company. It is focused on developing dHydronator, a sanitizing herb dryer. The main function of the dHydronator is to accelerate the drying time of an herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis. It will reduce the drying time for cannabis from 10-14 days down to less than 14 hours.

Executives

Hiro Tanaka	director, officer: Vice President	3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Smith Adrian J R	director, officer: Chair of the Board	119 SPRINGLINE DRIVE, VERO BEACH FL 32963
Jamie Mann	director, 10 percent owner, officer: CEO, CFO	3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Eden Ho	director, officer: CEO	701 XUANG MI HU ROAD, XI YUAN, FUTIAN, SHENZHEN F4 XXXXXX